Mutagen-DNA adducts

A *mutagen-DNA adduct* is a covalent complex formed when a mutagenic chemical reacts with DNA, usually at nucleophilic sites on DNA bases such as guanine or adenine[7][3][1]. The resulting adduct can miscode or block DNA replication and/or transcription, promoting mutagenesis and sometimes triggering cell death or carcinogenesis. Many environmental, dietary, or endogenous mutagens (e.g., polycyclic aromatic hydrocarbons, aromatic amines, certain chemotherapeutic drugs, metabolites of lipid peroxidation) form DNA adducts as part of their genotoxic mechanism. Their structural diversity and biological impact depend on the type of mutagen and the specific site/modification on the DNA. DNA adducts are key biomarkers for assessing exposure to genotoxic agents and are relevant in the molecular epidemiology of cancer risk[7][3][2][1]. Note: - "Mutagen-DNA adduct" is not a conventional drug target—rather, it is a class of chemical DNA lesions. - While some clinical approaches target DNA adduct *repair* processes (e.g., MGMT inhibitors in glioblastoma, exploiting DNA adduct persistence for cancer cytotoxicity), the adduct itself is not a molecular target in the usual sense of receptors or enzymes[2]. - The correct structure for structured annotation is to flag this entity as "is_incorrect: true" for molecular targeting purposes, though it is important in toxicology, biomonitoring, and cancer biology contexts.

Other names

DNA adductgenotoxic DNA lesioncarcinogen-DNA adductmutagenic DNA adduct

For DNA-targeting chemotherapeutic drugs: Covalent DNA adduct formation causing cytotoxicity via DNA damage-induced apoptosis or interference with replication (e.g., alkylating agents, platinum compounds) Some agents act by inhibiting DNA repair of adducts (e.g., MGMT inhibitors)